Anti-inflammatory function of Alzheimer’s disease drugs revealed
Points way to development of more efficient treatment
The mechanism in anti-Alzheimers disease drugs that inhibits the production of a destructive, inflammation-causing protein in the brain has been revealed by researchers at the Hebrew university of Jerusalem.
Their work, described in a recent issue of the American journal, Annals of Neurology, is likely to lead to the development of more efficient drugs than are currently in use for treating Alzheimers Disease as well as other neurological conditions resulting from infections, autoimmune diseases such as multiple sclerosis, or brain inflammation resulting from trauma or stroke.
The research team working on this project was headed by Prof. Raz Yirmiya of the Psychology Department at the Hebrew University, Dr. Yehuda Pollak, a post-doctoral fellow in Prof. Yirmiyas laboratory; and in cooperation with Hermona Soreq, the Charlotte Slesinger Professor of Cancer Studies at the Silberman Institute of Life Sciences at the Hebrew University, and Prof. Tamir Ben-Hur of the Hebrew University Faculty of Medicine.
Alzheimers Disease is a degenerative disease of the brain, characterized by a deterioration of both cognitive and physical abilities. It first affects memory and the ability to carry out complex, coordinated tasks. It also can bring on depression, inattention and outbursts of anger. In a more progressive stage, the disease can cause difficulties in the ability to perform even simple tasks such as speaking and comprehending, eating and sleeping. The affected person can even forget his name and identity.
The medicines administered today to Alzheimers Disease patients focus on preventing the breakdown of acetylcholine, a chemical produced by brain cells which transmits information within the brain and is vitally involved in cognitive processes that include memory, attention and thought. Because acetylcholine-producing cells are among the first to die in Alzheimers Disease patients, drug-induced elevation of acetylcholine levels partially attenuates the cognitive deterioration.
In recent years it has been shown that another pathological process that occurs in the brain of Alzheimers Disease patients is excessive immune activation and inflammation, which are induced by overproduction of an inflammation-producing protein called interleukin-1, as well as a few other related compounds. This process can impair the functioning of nerve cells and can even lead to their death. Furthermore, genetic alterations in the interleukin-1 gene have been associated with increased risk for the appearance and severity of Alzheimers Disease symptoms.
The Hebrew University researchers found that anti-Alzheimers Disease drugs currently in use not only block the activity of the enzyme responsible for breaking down acetylcholine but also cause a marked reduction in the production of interleukin-1. Furthermore, they describe the use of a novel drug (EN101), developed by Prof. Soreqs team, which produces these effects in a more efficient way than known heretofore by destroying the molecular antecedent (messenger RNA) of the enzyme, rather than simply blocking the enzymes activity.
In a series of experiments, conventional anti-Alzheimers Disease drugs, as well as the novel drug EN101, were injected into mice with brain inflammation. It was found that these injections reduced significantly the activity of the enzyme that breaks down acetylcholine and blocked almost entirely the production of interleukin-1.
“These findings suggest a new role for acetylcholine in the brain,” said Prof. Yirmiya. “When the anti-Alzheimers Disease drugs block the enzyme which breaks down acetylcholine, the level of this chemical in the brain goes up, and there is a reduction of the production of the inflammatory material, interleukin-1, and its destructive influence in the brain.”
“The discovery of this mechanism in the anti-Alzheimers Disease medicines points the way towards development of new forms of these medicines which will block even more efficiently and specifically the inflammatory and destructive activity of inteleukin-1,” Prof. Yirmiya stressed. “Beyond that, it is likely that the drugs that are currently used for treatment of Alzheimers Disease, and particularly the new drug EN101, will also be effective in dealing with other inflammatory illnesses.”
Media Contact
More Information:
http://www.huji.ac.ilAll latest news from the category: Life Sciences and Chemistry
Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.
Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.
Newest articles
Bringing bio-inspired robots to life
Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…
Bella moths use poison to attract mates
Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…
AI tool creates ‘synthetic’ images of cells
…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…